The Scottish Investment Bank is the investment arm of Scottish Enterprise.
The funding round was led by Equity Gap investors and the Scottish Investment Bank to accelerate customer growth and expand the team.
"Diverting an aircraft is an expensive and technically complex business. Although many carriers have voice support to doctors on the ground, it is often difficult for them to ‘review and recommend’ because of limited data."
The funding round was led by Mercia to support pre-clinical testing and manufacturing as the company prepares for clinical trials.
"Our goal is to bring much-needed improvement to the lives of three million dialysis patients. This investment allows us to take a big step towards this, and we are delighted to have won the backing of a consortium of smart, well-funded investors."
The financing round was led by Archangel Investors to support ongoing Phase IIa trials for its lead antibiotic.
"There remains a desperate need for novel treatments in our armoury to treat C. difficile infections. The work that MGB Biopharma is undertaking is both important and innovative and the results that have been achieved so far have been very encouraging."
The Edinburgh medical device firm secured backing from Archangels and the Scottish Investment Bank to prepare for its American market entry.
"We are delighted by the continuing commitment of our existing investors in this financing. This new investment allows us to continue to execute our strategy as we anticipate PMA approval for our CALCIVIS Imaging System later this year from FDA. We remain very confident in the potential of this new approach to preventive dentistry in the US, when it is launched in the world’s largest dentistry market in 2020. This optimism has been reinforced by our experience in the UK, where the CALCIVIS Imaging System has been shown to provide reliable, visualisation of demineralisation enabling bespoke, evidence-based preventive treatment for dental caries patients."
Epidarex Capital led the Series A round for the drug toxicity testing specialist.
"Since its inception, Clyde Biosciences has been working hard to meet our clients’ needs in improving outcomes in drug development. This investment, led by Epidarex Capital, will help propel Clyde Biosciences to a new level, allowing us to strengthen our team, reinforce our commercial offering and broaden our geographic reach. We welcome the support of our investment partners and look forward to an exciting future."
